By Ian Walker AstraZeneca shares are up and leading the FTSE 100 index risers after the company said that its lung-cancer treatment Tagrisso, together with.
French pharmaceuticals giant Sanofi on Thursday said it would be halting development of a promising cancer treatment after the cutting-edge candidate failed.
By Chris Wack Intensity Therapeutics shares doubled to $9.09 after the company said it saw positive data from its Phase 2 trial of INT230-6 in patients with.